Literature DB >> 18534981

Mechanisms involved in the reduction of GABAA receptor alpha1-subunit expression caused by the epilepsy mutation A322D in the trafficking-competent receptor.

Clarrisa A Bradley1, Changiz Taghibiglou, Graham L Collingridge, Yu Tian Wang.   

Abstract

A mutation in the alpha1-subunit (A322D) of GABA(A)Rs is responsible for juvenile myoclonic epilepsy in a large Canadian family. Previous work has identified that this mutant affects the cell expression and function of recombinant GABA(A)Rs, expressed in HEK293 cells. Here we have extended these observations by showing that the mutation promotes association with the endoplasmic reticulum chaperone calnexin and accelerates the degradation rate of the subunits approximately 2.5-fold. We also find that the mutation causes the subunit to be degraded largely by a lysosomal-dependent process. Furthermore, we find that the mutation results in receptors that are inserted into the plasma membrane but are more rapidly endocytosed by a dynamin and caveolin1-dependent mechanism. These results suggest that the mutant subunit can form functional receptors, but that these have a shorter lifetime on the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18534981     DOI: 10.1074/jbc.M801708200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Agonist-dependent endocytosis of γ-aminobutyric acid type A (GABAA) receptors revealed by a γ2(R43Q) epilepsy mutation.

Authors:  Severine Chaumont; Caroline André; David Perrais; Eric Boué-Grabot; Antoine Taly; Maurice Garret
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

Review 3.  GABAA receptor trafficking-mediated plasticity of inhibitory synapses.

Authors:  Bernhard Luscher; Thomas Fuchs; Casey L Kilpatrick
Journal:  Neuron       Date:  2011-05-12       Impact factor: 17.173

Review 4.  Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2017-11-15       Impact factor: 4.030

5.  The developmental evolution of the seizure phenotype and cortical inhibition in mouse models of juvenile myoclonic epilepsy.

Authors:  Fazal Arain; Chengwen Zhou; Li Ding; Sahar Zaidi; Martin J Gallagher
Journal:  Neurobiol Dis       Date:  2015-06-06       Impact factor: 5.996

6.  Combining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated γ-aminobutyric acid, type A (GABAA) receptors.

Authors:  Dong-Yun Han; Xiao-Jing Di; Yan-Lin Fu; Ting-Wei Mu
Journal:  J Biol Chem       Date:  2014-11-18       Impact factor: 5.157

7.  SAHA enhances Proteostasis of epilepsy-associated α1(A322D)β2γ2 GABA(A) receptors.

Authors:  Xiao-Jing Di; Dong-Yun Han; Ya-Juan Wang; Mark R Chance; Ting-Wei Mu
Journal:  Chem Biol       Date:  2013-11-07

8.  Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells.

Authors:  Kunal P Patel; Carolyn B Coyne; Jeffrey M Bergelson
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

Review 9.  mRNA surveillance and endoplasmic reticulum quality control processes alter biogenesis of mutant GABAA receptor subunits associated with genetic epilepsies.

Authors:  Robert L Macdonald; Jing-Qiong Kang
Journal:  Epilepsia       Date:  2012-12       Impact factor: 5.864

10.  Molecular pathology of genetic epilepsies associated with GABAA receptor subunit mutations.

Authors:  Robert L Macdonald; Jing-Qiong Kang
Journal:  Epilepsy Curr       Date:  2009 Jan-Feb       Impact factor: 7.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.